Phosphorus Containing Patents (Class 514/48)
  • Patent number: 10278984
    Abstract: Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of preventing and treating cancer and infection by administration of guanosine or pro-drugs of guanosine, or a precursor of guanosine are also disclosed. Compositions of guanosine or a pro-drug of guanosine or precursor of guanosine may be formulated as pharmaceutical dosage forms and components can be assembled as kits. Methods for activating TLRs with guanosine to enhance an immune response and to potentiate/augment antiviral, antibacterial or anticancer effects of other antiviral, anti-bacterial and anticancer therapeutic agents are also disclosed.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 7, 2019
    Assignee: Nitor Therapeutics
    Inventor: Shanta Bantia
  • Patent number: 10005779
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1?,4?-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, RA, RB, W, X, Y, and Z are as described herein.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: June 26, 2018
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Gilles Gosselin, Cyril B. Dousson
  • Patent number: 9828410
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: November 28, 2017
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Patent number: 9707274
    Abstract: Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: July 18, 2017
    Assignee: HealthPartners Research & Education
    Inventor: William H. Frey, II
  • Patent number: 9394330
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 19, 2016
    Assignee: Alios BioPharma, Inc.
    Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Patent number: 9315797
    Abstract: Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: April 19, 2016
    Assignee: New England Biolabs, Inc.
    Inventors: Donald Johnson, Thomas C. Evans, Jr.
  • Patent number: 9309275
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: April 12, 2016
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
  • Patent number: 9109001
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: August 18, 2015
    Assignee: IDENIX PHARMACEUTICALS, INC.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Claire Pierra, Dominique Surleraux, Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
  • Patent number: 9095599
    Abstract: This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: August 4, 2015
    Assignee: Nanjing Molecular Research, Inc.
    Inventors: Junbiao Chang, Zheng Wang, Suping Zhou
  • Publication number: 20150141363
    Abstract: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: Guangyi Wang, Leonid Beigelman
  • Patent number: 9029345
    Abstract: An agent for inhibiting P-glycoproteins comprises a non-natural adenine ribose analog.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: May 12, 2015
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee
  • Publication number: 20150105341
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 16, 2015
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
  • Patent number: 8980865
    Abstract: Disclosed herein are phosphorothioate nucleotide analogs, such as thiophosphoroamidate prodrugs and thiophosphates (including ?-thiomonophosphates, ?-thiodiphosphates, and ?-thiotriphosphates), methods of synthesizing phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates and methods of treating viral infections, such as HCV, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: March 17, 2015
    Assignee: Alios BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman
  • Patent number: 8975299
    Abstract: The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.
    Type: Grant
    Filed: November 2, 2008
    Date of Patent: March 10, 2015
    Assignee: Enzymotec Ltd.
    Inventors: Fabiana Bar Yosef, Dori Pollod, Ariel Katz
  • Publication number: 20150056224
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereosiomers thereof.
    Type: Application
    Filed: May 18, 2014
    Publication date: February 26, 2015
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • Publication number: 20150056166
    Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
  • Publication number: 20150051167
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Jerome Deval, Marija Prhavc
  • Patent number: 8957045
    Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: February 17, 2015
    Assignee: Gilead Pharmasset LLC
    Inventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
  • Publication number: 20150025000
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering 2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-exadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide (Compound I), or a pharmaceutically acceptable salt thereof, and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. The other anti-HCV agent can be a HCV polymerase inhibitor, an HCV NS5A inhibitor, an HCV entry inhibitor, a cyclophilin inhibitor, or an internal ribosome entry site inhibitor. Preferably, the other anti-HCV agent is an HCV polymerase inhibitor. Also preferably, the other anti-HCV agent is an HCV NS5A inhibitor. Also preferably, the other anti-HCV agent is administered concurrently with Compound I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Applicant: ABBVIE INC.
    Inventors: Barry M. Bernstein, Scott C. Brun
  • Publication number: 20150011497
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: June 24, 2014
    Publication date: January 8, 2015
    Inventors: Leonid Beigelman, Jerome Deval, Zhinan Jin
  • Publication number: 20140356325
    Abstract: Compositions and methods relating to 2?-C-methyl nucleoside 5?-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2?-C-methyl nucleoside 5?-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection are described.
    Type: Application
    Filed: January 8, 2013
    Publication date: December 4, 2014
    Applicant: Ligand Pharmaceuticals Incorporated
    Inventors: Lin Zhi, K. Raja Reddy, Mark David Erion, Scott Hecker
  • Patent number: 8895531
    Abstract: The present invention includes compounds and compositions of ®-2?-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: November 25, 2014
    Assignee: RFS Pharma LLC
    Inventor: Junxing Shi
  • Patent number: 8877731
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: November 4, 2014
    Assignee: Alios Biopharma, Inc.
    Inventors: Leonid Beigelman, Jerome Deval, David Bernard Smith, Guangyi Wang, Vivek Kumar Rajwanshi
  • Publication number: 20140315850
    Abstract: The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2?,3?-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2?,3?-Dideoxy-2,-a-fluoro-2?-{3-C-methyl-nucleosides can be considered as one unique class of 2?,3?-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2?-fluorine-a mimics 2?-a-OH group.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 23, 2014
    Applicant: Nanjing Molecular Research, Inc.
    Inventors: Qiang Huang, Suping Zhou, Junbiao Chang
  • Publication number: 20140303239
    Abstract: The present disclosure is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogs thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 9, 2014
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Jerry W. Shay, Sergei M. Gryaznov
  • Publication number: 20140303108
    Abstract: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 9, 2014
    Inventors: Leonid Beigelman, David Bernard Smith, Jerome Deval, Vivek Kumar Rajwanshi
  • Publication number: 20140303107
    Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.
    Type: Application
    Filed: August 29, 2012
    Publication date: October 9, 2014
    Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harich Ravivarapu
  • Publication number: 20140294769
    Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 2, 2014
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
  • Patent number: 8846636
    Abstract: The disclosure provides nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary centers at the 3? position, the pharmaceutical formulations comprising the analogues, and methods of using the analogues and formulations for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: September 30, 2014
    Assignee: LCB Pharma Inc.
    Inventor: Yvan Guindon
  • Patent number: 8846638
    Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 30, 2014
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang
  • Publication number: 20140286903
    Abstract: This invention is directed to compounds of Formula (I) having the structure that are useful in the treatment of viral infections in mammals, particularly in humans, mediated, at least in part, by a virus in the Flaviviridae family of viruses.
    Type: Application
    Filed: November 8, 2012
    Publication date: September 25, 2014
    Applicants: INHIBITEX, INC., UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Stanley Chamberlain, John Vernachio, Srinivas K. Battina, Changalvala V.S. Ramamurty, C. Srinivas Rao, Chris McGuigan, Andrea Brancale
  • Publication number: 20140286945
    Abstract: Disclosed herein is a new and improved therapy for the treatment of diseases including cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. The method may also be employed in combination with existing chemotherapeutic agents to combat the drug resistance and enhance the therapeutic efficacy of conventional therapy.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 25, 2014
    Applicant: The Curators of the University of Missouri
    Inventors: Carl Freter, Indira Benakanakere
  • Publication number: 20140255339
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicants: Idenix Pharmaceuticals, Inc., Universite Montpellier II, Centre National de la Recherche Scientifique
    Inventors: Jean-Pierre SOMMADOSSI, Gilles GOSSELIN, Claire PIERRA, Christian PERIGAUD, Suzanne PEYROTTES
  • Publication number: 20140248241
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 4, 2014
    Inventors: Alistair James STEWART, Adel M. MOUSSA, Benjamin Alexander MAYES, Francois-Rene ALEXANDRE, Dominique SURLERAUX, Christophe Claude PARSY, Claire PIERRA, David DUKHAN, Gilles GOSSELIN
  • Publication number: 20140248242
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 4, 2014
    Inventors: Cyril B. DOUSSON, Benjamin Alexander MAYES, David DUKHAN, Adel M. MOUSSA, Alistair James STEWART
  • Patent number: 8815827
    Abstract: Myeloid differentiating agents can be used in the treatment of myeloid disorders.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: August 26, 2014
    Assignee: Case Western Reserve University
    Inventor: David Wald
  • Patent number: 8815828
    Abstract: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., breast cancer) by increasing DNA damage and reducing base excision repair (BER).
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: August 26, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Satya Narayan, Aruna S. Jaiswal, David A. Ostrov
  • Patent number: 8815829
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3?-azido-2?,3?-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: August 26, 2014
    Assignees: RFS Pharma, LLC, Emory University, University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Raymond F. Schinazi, John W. Mellors, Nicolas Paul Sluis-Cremer, Steven J. Coats, Richard Anthony Whitaker, Brian David Herman, Jong Hyun Cho, Longhu Zhou, Hongwang Zhang
  • Publication number: 20140234428
    Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 21, 2014
    Applicant: Cymbiotics, Inc.
    Inventors: Raj R. Barathur, Jack Bain Bookout
  • Patent number: 8809265
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: August 19, 2014
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Publication number: 20140221304
    Abstract: The present invention relates to 5?-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3? are as defined herein. The present invention also relates to compositions comprising at least one 5?-Substituted Nucleoside Analog, and methods of using the 5?-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: July 10, 2012
    Publication date: August 7, 2014
    Inventors: Vishal A. Verma, Ashok Arasappan, F. George Njoroge, Kevin X. Chen
  • Publication number: 20140205566
    Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: wherein R1, R2 and R3 are as defined herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 24, 2014
    Applicant: NOVARTIS AG
    Inventors: Lv LIAO, Fumiaki YOKOKAWA, Gang WANG
  • Publication number: 20140206640
    Abstract: The present invention relates to 2?-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Azido Substituted Nucleoside Derivative, and methods of using the 2?-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: April 11, 2012
    Publication date: July 24, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Vinay Girijavallabhan, F. George Njoroge, Stephane Bogen, Frank Bennett, Vishal Verma, Ashok Arasappan, Kevin X. Chen, Ying Huang, Angela Kerekes, Latha Nair, Dimitri Pissarnitski, Qun Dang, Ian Davies, David B. Olsen, Andrew Stamford, Joseph P. Vacca
  • Patent number: 8772263
    Abstract: Methods and compositions for protecting muscarinic receptor(s) in a subject from at least one carcinogenic or toxic metal by administration of a pyrophosphate analog. Methods and compositions for preventing at least one disease induced or caused by metals compromising the function of muscarinic receptors in a subject by administration of a pyrophosphate analog. Methods and compositions for reducing toxic action of metal ions and for reducing poisoning by metals by administering a pyrophosphate analog.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: July 8, 2014
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, John Randall Fawcett
  • Patent number: 8771681
    Abstract: Methods and compositions for protecting and treating a muscarinic receptor in an animal or plant from bacterial, fungal, algo or algae infections through administration of at least one pyrophosphate analog.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: July 8, 2014
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, John Randall Fawcett
  • Patent number: 8765711
    Abstract: Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: July 1, 2014
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, John Randall Fawcett
  • Publication number: 20140178338
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 26, 2014
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN
  • Patent number: 8759510
    Abstract: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: June 24, 2014
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Ganapati Reddy Pamulapati, Bruce S. Ross, Michael Joseph Sofia
  • Patent number: 8759317
    Abstract: A method of treating cancer through use of guanosine 3?,5?-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 ?M), 84% (1 mM), 31% (1 ?M), and 30% (1 ?M), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 ?M concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 24, 2014
    Assignee: University of South Florida
    Inventor: David L. Vesely
  • Patent number: 8759318
    Abstract: Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 24, 2014
    Assignees: Inhibitex, Inc., University College Cardiff Consultants Limited
    Inventors: Stanley Chamberlain, Jeff Hutchins, Karolina Madela, Christopher McGuigan, John Vernachio, Mohamed Aljarah, Arnaud Gilles